ContraFect's EBIT per Share for the
three
months ended in Sep. 2023 was $-0.62.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-18.13.
During the past 3 years, the average EBIT per Share Growth Rate was 25.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 26.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 29.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ContraFect's EBIT per Share or its related term are showing as below:
CFRXQ'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 18.7 Med: 31.2 Max: 37
Current: 25.9
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of ContraFect was 37.00% per year. The lowest was 18.70% per year. And the median was 31.20% per year.
CFRXQ's 3-Year EBIT Growth Rate is ranked better than 77.48% of 1301
companies
in the Biotechnology industry
Industry Median: 3.4
vs CFRXQ: 25.90
ContraFect's EBIT for the
three
months ended in Sep. 2023 was $-6.68 Mil.
ContraFect EBIT per Share Historical Data
The historical data trend for ContraFect's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ContraFect (OTCPK:CFRXQ) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ContraFect EBIT per Share Related Terms
Thank you for viewing the detailed overview of ContraFect's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CFRXQ has been successfully added to your 